Kristen Henretty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kristen Henretty has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Tami L. Mark
RTI International, Research Triangle Park, North Carolina
3 shared publications Marylou Gilbert
2 shared publicationsAlan Barnosky
1 shared publication- Brent Gibbons
RTI International
1 shared publication - Deborah G. Steinberg
Legal Action Center, 810 1st Street, NE, Suite 200, Washington DC 20002, USA
1 shared publication - Ellen M. Weber
Legal Action Center, 810 1st Street, NE, Suite 200, Washington DC 20002, USA
1 shared publication
Latest Publications
- Open Access
- 4 July 2026
- Published by Elsevier in SSRN Electronic Journal
Urine drug testing practices at Opioid Treatment Programs in a large health system, 2018-2025
BackgroundThe COVID-19 public health emergency prompted substantial changes in opioid treatment program (OTP) practices, including expanded methadone take-home dosing and telehealth use. While many of these changes persisted after the emergency period, less is known about how drug testing practices were altered and whether any changes were sustained over time.MethodsWe examined monthly trends in drug testing among patients receiving methadone for opioid use disorder at 112 OTP clinics operated by a large national treatment organization. Administrative electronic medical record data from January 2018 through June 2025 were used to construct patient-level testing measures. A testing event was defined as any day in which a patient received at least one drug test. Interrupted time series analyses assessed changes in the level and trend of average monthly testing at the onset of the COVID-19 pandemic in March 2020.ResultsIn January 2018, patients received 1.13 urine drug tests on average. Testing frequencies increased by 0.003 per month on average until February 2020 (p = 0.016). In the first two months of the COVID-19 pandemic testing frequency decreased to 1.00-1.02 a month (about an 11% decline (p = 0.006)). Testing levels returned to pre-pandemic levels by May 2020. They trended slightly downward through the end of the study period and were at 1.14 on average in June 2025 (p = 0.033).ConclusionsDrug testing frequency modestly decreased during the first months of the COVID-19 pandemic but quickly returned to pre-pandemic levels. This may reflect the fact that urine testing regulations for OTPs were not changed as part of broader post-pandemic federal regulatory reforms. Future research should focus on how to best tailor drug testing practices to improve patient engagement, safety, and recovery.
- 4 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessUrine drug testing practices at Opioid Treatment Programs in a large health system, 2018-2025
BackgroundThe COVID-19 public health emergency prompted substantial changes in opioid treatment program (OTP) practices, including expanded methadone take-home dosing and telehealth use. While many of these changes persisted after the emergency period, less is known about how drug testing practices were altered and whether any changes were sustained over time.MethodsWe examined monthly trends in drug testing among patients receiving methadone for opioid use disorder at 112 OTP clinics operated by a large national treatment organization. Administrative electronic medical record data from January 2018 through June 2025 were used to construct patient-level testing measures. A testing event was defined as any day in which a patient received at least one drug test. Interrupted time series analyses assessed changes in the level and trend of average monthly testing at the onset of the COVID-19 pandemic in March 2020.ResultsIn January 2018, patients received 1.13 urine drug tests on average. Testing frequencies increased by 0.003 per month on average until February 2020 (p = 0.016). In the first two months of the COVID-19 pandemic testing frequency decreased to 1.00-1.02 a month (about an 11% decline (p = 0.006)). Testing levels returned to pre-pandemic levels by May 2020. They trended slightly downward through the end of the study period and were at 1.14 on average in June 2025 (p = 0.033).ConclusionsDrug testing frequency modestly decreased during the first months of the COVID-19 pandemic but quickly returned to pre-pandemic levels. This may reflect the fact that urine testing regulations for OTPs were not changed as part of broader post-pandemic federal regulatory reforms. Future research should focus on how to best tailor drug testing practices to improve patient engagement, safety, and recovery.
- 1 November 2025
- Published by Hogrefe Publishing Group in Crisis
- Vol. 46 (6) , 327-333
Evaluation of the Effect of Arizona’s Crisis Response System on Hospitalizations for Behavioral Health Conditions
Background: US federal and state governments are investing in comprehensive behavioral health crisis system reforms. These reforms aim to prevent suicide, limit police involvement in crises, and reduce reliance on hospitals and emergency departments. Arizona’s reform is considered a model for other states. Aims: We evaluated whether Arizona’s crisis system reform was associated with reductions in behavioral health-related hospitalizations. Method: We used a comparative interrupted time series design to assess Arizona’s implementation of their crisis response system in 2015. We used 2011–2018 Healthcare Cost and Utilization Project (HCUP) State Inpatient Dataset (SID) data and selected Colorado, Kentucky, Michigan, New Jersey, New Mexico, and Washington as comparison states. Results: Arizona’s annual behavioral health-related hospital discharge rate per 100,000 population decreased from 686.3 in 2011 to 673.7 in 2014 and increased from 759.3 in 2016 to 955.7 in 2019. The comparative interrupted time series analyses revealed that implementation of Arizona’s crisis system was not associated with a change in the rate of behavioral health hospitalizations. Limitations: There may be some unmeasured, time-varying factors related to the rate of behavioral health-related hospitalizations between Arizona and our comparison states that we are not accounting for. Also, hospitals switched from using ICD-9 to ICD-10 codes in 2015, the same year as Arizona implemented their crisis system. Conclusions: More research is needed to confirm whether and how comprehensive crisis response systems impact behavioral health-related hospitalizations.
- 1 November 2025
- Published by Hogrefe Publishing Group in Crisis
- Vol. 46 (6) , 327-333
Evaluation of the Effect of Arizona’s Crisis Response System on Hospitalizations for Behavioral Health Conditions
Background: US federal and state governments are investing in comprehensive behavioral health crisis system reforms. These reforms aim to prevent suicide, limit police involvement in crises, and reduce reliance on hospitals and emergency departments. Arizona’s reform is considered a model for other states. Aims: We evaluated whether Arizona’s crisis system reform was associated with reductions in behavioral health-related hospitalizations. Method: We used a comparative interrupted time series design to assess Arizona’s implementation of their crisis response system in 2015. We used 2011–2018 Healthcare Cost and Utilization Project (HCUP) State Inpatient Dataset (SID) data and selected Colorado, Kentucky, Michigan, New Jersey, New Mexico, and Washington as comparison states. Results: Arizona’s annual behavioral health-related hospital discharge rate per 100,000 population decreased from 686.3 in 2011 to 673.7 in 2014 and increased from 759.3 in 2016 to 955.7 in 2019. The comparative interrupted time series analyses revealed that implementation of Arizona’s crisis system was not associated with a change in the rate of behavioral health hospitalizations. Limitations: There may be some unmeasured, time-varying factors related to the rate of behavioral health-related hospitalizations between Arizona and our comparison states that we are not accounting for. Also, hospitals switched from using ICD-9 to ICD-10 codes in 2015, the same year as Arizona implemented their crisis system. Conclusions: More research is needed to confirm whether and how comprehensive crisis response systems impact behavioral health-related hospitalizations.
- 16 January 2023
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 244, 109778
The cost of opioid use disorder-related conditions in Medicare
- 16 January 2023
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 244, 109778
The cost of opioid use disorder-related conditions in Medicare
- Open Access
- 1 January 2021
- Published by SAGE Publications in Substance Abuse: Research and Treatment
- Vol. 15
Impact of the Coronavirus Pandemic on Substance Use Disorder Treatment: Findings from a Survey of Specialty Providers in California
Background: As the coronavirus pandemic public health emergency begins to ebb in the United States, policymakers and providers need to evaluate how the addiction treatment system functioned during the public health emergency and draw lessons for future emergencies. One important question is whether the pandemic curtailed the use of addiction treatment and the extent to which telehealth was able to mitigate access barriers. Methods: To begin to answer this question, we conducted a survey of specialty addiction treatment providers in California from June 2020 through July 2020. The survey focused specifically on provider organizations that served Medicaid beneficiaries. Results: Of the 133 respondents, 50% reported a decrease in patients since the stay-at-home order in March 2020, with the largest decline among new patients, and 58% said more patients were relapsing. Eighty-one percent of providers said that telemedicine use had increased since the stay-at-home order. Most said that telemedicine had moderately (48%) or completely (30%) addressed access barriers. Conclusion: More efforts are needed to ensure that patients, and in particular new patients, receive addiction treatment during public health emergencies.
- 1 January 2021
- Published by SAGE Publications in Substance Abuse: Research and Treatment
- Vol. 15
Open AccessImpact of the Coronavirus Pandemic on Substance Use Disorder Treatment: Findings from a Survey of Specialty Providers in California
Background: As the coronavirus pandemic public health emergency begins to ebb in the United States, policymakers and providers need to evaluate how the addiction treatment system functioned during the public health emergency and draw lessons for future emergencies. One important question is whether the pandemic curtailed the use of addiction treatment and the extent to which telehealth was able to mitigate access barriers. Methods: To begin to answer this question, we conducted a survey of specialty addiction treatment providers in California from June 2020 through July 2020. The survey focused specifically on provider organizations that served Medicaid beneficiaries. Results: Of the 133 respondents, 50% reported a decrease in patients since the stay-at-home order in March 2020, with the largest decline among new patients, and 58% said more patients were relapsing. Eighty-one percent of providers said that telemedicine use had increased since the stay-at-home order. Most said that telemedicine had moderately (48%) or completely (30%) addressed access barriers. Conclusion: More efforts are needed to ensure that patients, and in particular new patients, receive addiction treatment during public health emergencies.